Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
Compared with TDF, TAF use was associated with an approximately 71% reduction in HCC hazard. Larger cohorts with longer follow-up are warranted to corroborate these observations.
Authors
- Seung Kak Shin (ORCID: https://orcid.org/0000-0002-5120-5300)
- Soon Koo Baik (ORCID: https://orcid.org/0000-0001-6245-2537)
- Sun Young Yim (ORCID: https://orcid.org/0000-0001-7346-5974)
- Seul Ki Han (ORCID: https://orcid.org/0000-0002-8294-3517)
- Seong Hee Kang (ORCID: https://orcid.org/0000-0002-0783-509X)
- Jong Eun Yeon (ORCID: https://orcid.org/0000-0002-0510-7371)
- Young Kul Jung (ORCID: https://orcid.org/0000-0002-6566-1382)
- Tae Hyung Kim (ORCID: https://orcid.org/0000-0002-7747-4293)
- Moon Young Kim (ORCID: https://orcid.org/0000-0001-8881-2027)
- Young‐Sun Lee
- Hyung Joon Yim
- Yeon Seok Seo
- Oh. Sang Kwon
- Ji Hoon Kim
Institutions
- Gachon University (KR)
- Yonsei University (KR)
- Korea University (KR)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1111/jgh.70326
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00